British Biotech was a British based biotech company.

PropertyValue
dbpedia-owl:Company/industry
dbpedia-owl:Organisation/foundationDate
  • 1986-01-01 00:00:00 (xsd:date)
dbpedia-owl:Organisation/keyPersonPosition
  • CEO
    Keith McCullagh, 1986-1998
    Elliot Goldstein, 1998-2002
    Tim Edwards, 2002-2003
    Chair
    Brian Richards, 1986-1998
    Christopher Hampson, 1998-2002
    Peter Fellner, 2002-2003
dbpedia-owl:Organisation/location
dbpedia-owl:Organisation/numberOfEmployees
  • 500 (xsd:integer)
dbpedia-owl:foundationDate
  • 1986-01-01 00:00:00 (xsd:date)
dbpedia-owl:industry
dbpedia-owl:keyPersonPosition
  • CEO
    Keith McCullagh, 1986-1998
    Elliot Goldstein, 1998-2002
    Tim Edwards, 2002-2003
    Chair
    Brian Richards, 1986-1998
    Christopher Hampson, 1998-2002
    Peter Fellner, 2002-2003
dbpedia-owl:location
dbpedia-owl:numberOfEmployees
  • 500 (xsd:integer)
dbpprop:abstract
  • British Biotech was a British based biotech company. British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, and was the first British biotechnology company to be publicly listed when it was floated on 1 July 1992 In 1996, despite having no compounds on or near the market, it was temporarily valued at nearly $2.5 billion, largely on the basis of its two main development drugs, marimastat (a novel matrix metalloprotease inhibitor for cancer treatment) and zacutex. In February 1998, Dr Andrew Millar was dismissed as Head of Clinical Research and went on to make allegations that "the Board were running a business plan consistent only with extreme and unfounded optimism" . These events were the subject of an inquiry by the House of Commons Select Committee on Science and Technology in August 1998 which absolved Dr Millar of any responsibility for the company’s problems. Subsequent investigations by the Securities and Exchange Commission, Food and Drug Administration, London Stock Exchange and the European Medicines Evaluation Agency found that British Biotech had willfully misled the public about the progress of marimastat and that unblinding data before the end of clinical trials does not necessarily invalidate the results. Marimastat underwent Phase III trials in collaboration with Schering-Plough Corporation. Further development of zacutex was abandoned due to poor clinical trial results. The corporate politics behind the downfall of British Biotech was later recorded for a BBC2 Series "Blood on The Carpet". In 2003, British Biotech merged with RiboTargets and then into Vernalis. The British Biotech company name disappeared after this merger and remaining staff integrated into the Vernalis organisation in Winnersh, Berkshire.
dbpprop:companyName
  • British Biotech ''plc''
dbpprop:defunct
  • 2003 (xsd:integer)
dbpprop:fate
  • Merged
dbpprop:foundation
  • 1986 (xsd:integer)
dbpprop:hasPhotoCollection
dbpprop:industry
dbpprop:keyPeople
  • CEO Keith McCullagh, 1986-1998 Elliot Goldstein, 1998-2002 Tim Edwards, 2002-2003 Chair Brian Richards, 1986-1998 Christopher Hampson, 1998-2002 Peter Fellner, 2002-2003
dbpprop:location
dbpprop:numEmployees
  • 500 (xsd:integer)
dbpprop:reference
dbpprop:successor
  • company merged into Vernalis
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • British Biotech was a British based biotech company.
rdfs:label
  • British Biotech
owl:sameAs
skos:subject
foaf:name
  • British Biotech plc
    (LSE:BBG Nasdaq:BBIOY)
foaf:page
is owl:sameAs of